$MNOV upturn at breakout
Nasdaq GM $4.22
Called 9/2/14 $2.35
Website
Shares Outstanding: 29.96M
Float: 26.74M
% Held by Insiders: 22.50%
% Held by Institutions: 8.50%
Shares Short (as of Jan 15, 2016): 491.86K
Short Ratio (as of Jan 15, 2016): 11.52
Short % of Float (as of Jan 15, 2016): 2.26%
Shares Short (prior month): 303.75K
Headlines
Company Profile - MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
Nasdaq GM $4.22
Called 9/2/14 $2.35
Website
Shares Outstanding: 29.96M
Float: 26.74M
% Held by Insiders: 22.50%
% Held by Institutions: 8.50%
Shares Short (as of Jan 15, 2016): 491.86K
Short Ratio (as of Jan 15, 2016): 11.52
Short % of Float (as of Jan 15, 2016): 2.26%
Shares Short (prior month): 303.75K
Headlines
Company Profile - MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.
